ArticleJournal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology2026
Sequence Variation of Epstein-Barr Virus EBNA-1 Gene in Central Nervous System Inflammatory Demyelinating Diseases in Pakistan.
Article in Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
CNS inflammatory demyelinating diseases (CNS-IDDs), including multiple sclerosis and related conditions, have increasingly been associated with Epstein-Barr virus (EBV). However, data on EBV genetic diversity, particularly regarding EBNA-1 gene variants, across different CNS-IDD subtypes in South Asian populations remain limited. This study examined EBV DNA prevalence and EBNA-1 sequence variation in 40 patients with CNS-IDD and 40 healthy controls from Pakistan. EBV DNA was found in 21 of 80 samples (26%), with a significantly higher occurrence in CNS-IDD patients (16/40, 40%) compared to healthy controls (5/40, 13%) (p = 0.005, OR = 4.667). All EBV-positive samples clustered within the P-thr EBNA-1 variant, carrying consistent amino acid substitutions P476Q, A487T, S492C, and T524I, suggesting these are conserved features of the regionally circulating strain. These findings provide a foundation for further studies to explore the pathogenic significance of EBNA-1 variation linked with CNS-IDDs in the region.
Indexed as
Identifiers
42603225What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.